Ocular Therapeutix Inc. (NASDAQ:OCUL) is a top biotech stock with high potential, with Piper Sandler raising its price target to $31. The firm discussed newly disclosed trial designs and raised sales estimates for AXPAXLI to $3.2 billion based on confidence in Phase 3 programs.

Ocular Therapeutix Inc. (NASDAQ:OCUL) is a biopharmaceutical company specializing in eye-related therapies like Dextenza, OTX-TP, and OTX-TIC. While OCUL shows investment potential, consider AI stocks for greater upside. A free report highlights an undervalued AI stock poised to benefit from current trends.

For more insights, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey. No disclosures in this article.

Read more at Yahoo Finance: Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21